A5091017886- HIV-related health complications and treatments
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Systemic Lupus Erythematosus Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- Vasculitis and related conditions
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Venous Thromboembolism Diagnosis and Management
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Sarcoidosis and Beryllium Toxicity Research
- Systemic Sclerosis and Related Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- IgG4-Related and Inflammatory Diseases
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Inflammatory Myopathies and Dermatomyositis
- Mycobacterium research and diagnosis
- Blood Coagulation and Thrombosis Mechanisms
- Bone and Joint Diseases
- Folate and B Vitamins Research
Hôpital Pellegrin
1999-2025
Médecins du Monde
2025
Hôpital Paul-Brousse
2025
Hôpital Saint-André
2013-2024
Bordeaux Population Health
2009-2024
Inserm
2011-2024
Centre Hospitalier Universitaire de Bordeaux
2014-2024
Université de Bordeaux
2010-2024
Assistance Publique – Hôpitaux de Paris
2014-2024
Université Paris Cité
2022-2024
Background: There is a high prevalence of bone demineralization among HIV-infected patients but mechanisms alteration turnover are still unclear and it thought to be multifactorial. Methods: A cross-sectional survey 492 within the Aquitaine cohort estimated osteoporosis/osteopenia investigated associated factors. Bone mineral density total body, lumbar spine femoral neck was measured by dual-energy X-ray absorptiometry. Multivariable analyses association with HIV disease status, treatment...
Objectives The aim of the study was to estimate rates cardiovascular disease (CVD) events after stopping smoking in patients with HIV infection. Methods Patients who reported status and no previous CVD prior enrolment Data Collection on Adverse Events Anti-HIV Drugs (D:A:D) were included this study. Smoking is collected at each visit as current smoker (yes/no) ever (yes/no). Time since calculated for persons had during follow-up subsequently. Endpoints were: myocardial infarction (MI);...
Large unselected studies on representative samples of HIV-infected patients with a whole battery neuropsychological tests and cerebral MRI scan are required to assess the frequency neurocognitive impairment (NCI), determinants mild disorders (MNDs), or HIV-associated dementia (HAD) relationship between NCI findings.Investigation 400 consecutively enrolled HIV-1-infected adults from ANRS CO3 Aquitaine Cohort, using standardized chosen achieve consistency Frascati's criteria. Half had allowing...
Bortezomib is an active agent in AL amyloidosis and responses to this drug combination with cyclophosphamide dexamethasone are both rapid deep. Here we present international, multicenter series of 60 patients Mayo Clinic stage III cardiac assess the impact regimen improving outcomes poor-risk group. The median follow-up for entire cohort 11.8 months. overall response rate was 68%. In a landmark analysis, examining who survived more than 3 months, 86%. A seen 32% patients. estimated 1-year...
The objective of this study was to estimate the prevalence and risk factors for clinical lipodystrophy (LD) metabolic disorders in human immunodeficiency virus (HIV) type 1-infected patients. A cross-sectional survey Aquitaine Cohort performed January 1999. diagnosis LD categorized as fat wasting (FW), peripheral accumulation (FA), mixed syndromes (MS). Of 581 patients studied, 61% were treated with protease inhibitors. overall 38% (95% confidence interval [CI], 32–42): FW 16% CI, 13–18);...
Objective: To study hepatic cytolysis in patients treated by highly active antiretroviral therapy (HAART) with protease inhibitor or two nucleoside reverse transcriptase inhibitors (NRTIs). Methods: We selected of the Aquitaine Cohort who initiated HAART NRTIs before 1 January 1998, had alanine amino-transferase (ALT) ≤ 200 IU/l at baseline and least one follow-up measure. Cox model was used to association between occurrence severe (ALT>200 IU/l) age, gender, HIV transmission group, CD4 CD8...
In treated HIV-infected patients, mortality is now dominated by non-AIDS–related causes in which tobacco smoking a predominant risk factor. The implementation of cessation programs therefore warranted to increase survival but should consider the specificities this population be successful. All outpatients consulting May June 2004 within ANRS CO3 Aquitaine Cohort patients were asked complete self-administered questionnaire including questions about and other drugs consumption, Fagerström Test...
Human immunodeficiency virus (HIV)-infected patients are at higher risk of malignancies. In addition to traditional determinants, a specific deleterious effect HIV and is speculated. We aimed studying the association between immunological virological characteristics HIV-infected in care acquired syndrome (AIDS)-defining non-AIDS-defining malignancies.Patients consecutively enrolled hospital-based Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort were included if duration...
AbstractBACKGROUND. Highly active antiretroviral therapies (HAART) in HIV-infected patients are often associated with lipodystrophy syndrome and metabolic disorders. Atherogenic lipid profile could expose these to atheromatous cardiovascular disease. We describe carotid artery intima-media thickness (IMT), a surrogate marker of atherosclerosis, according HIV status, treatment, conventional risk factors. METHOD. In multicenter prospective cohort study we have surveyed subjects IMT measurement...
Objectives To describe the causes of death in HIV‐infected patients era highly active antiretroviral therapy (HAART). Method A retrospective survey conducted Bordeaux, France. Medical records all deaths that had occurred 1998 and 1999 amongst followed within Aquitaine cohort were reviewed by same physician. Immediate underlying described, taking into account morbidity at time death. Results Sixty‐six 1998, 41 1999. Sixty‐seven per cent deceased male. Median age was 43 years (range 25–71),...
Objectives HIV‐infected patients are at risk of atherosclerosis and cardiovascular diseases. In a 12‐month follow‐up study, we aimed to investigate changes in carotid intima–media thickness (IMT), surrogate marker atherosclerosis, its determinants HIV‐1‐infected patients. Methods Our multicentre prospective longitudinal cohort study included 346 patients, for each whom two IMT measurements were taken by B‐mode ultrasonography baseline (M0) 1 year later (M12). Results We observed significant...
To provide up-to-date assessments of locomotor function in HIV-infected patients and to identify potential determinants impaired function.Cross-sectional study 324 HIV-1-infected adults from the French Agency for AIDS Hepatitis Research (ANRS) CO3 Aquitaine Cohort using standardized tests.Patients underwent testing assessing balance, walking ability, functional capacity lower limb muscle performance. Poor test performance was defined by cut-offs based on age-specific data general population....
We evaluated the impact of cytomegalovirus (CMV)–induced immune responses, autoimmune-induced and microbial translocation on activation in 191 human immunodeficiency virus type 1–infected patients from ANRS CO3 Aquitaine Cohort. All enrolled subjects had achieved long-term virological suppression during receipt combination antiretroviral therapy (cART). HLA-DR+/CD38+ expression was 16.8% among CD8+ T cells. Independent age, CD4+ T-cell count, 16S ribosomal DNA load, regulatory positive...
To assess changes in locomotor function HIV-infected patients and to evaluate the determinants of variations lower limb muscle performance.Longitudinal study within ANRS CO3 Aquitaine Cohort.Standardized tests, including global functional capacity [6-min walk distance (6MWD)] performance tests [five times sit-to-stand (5STS) test], were performed adults at baseline 2-year follow-up. Evolution performances 5STS time studied linear mixed-effects models.At (354 patients, 90% on antiretroviral...
Objective To compare HIV-disease progression according to changes of plasma HIV RNA observed in the year following initiation a new antiretroviral treatment. Design Prospective cohort treated with two nucleoside analogues or triple combination including protease inhibitor. Methods A Cox model was used estimate effect viral response during first after treatment on subsequent occurrence AIDS-defining events death. Viral fitted either as reduction initial 4–12 months month. Results Among 773...
Because of the known relationship between exposure to combination antiretroviral therapy and cardiovascular disease (CVD), it has become increasingly important intervene against risk CVD in human immunodeficiency virus (HIV)-infected patients. We evaluated changes factors for use lipid-lowering HIV-infected individuals assessed impact any on incidence myocardial infarction.The Data Collection Adverse Events Anti-HIV Drugs Study is a collaboration 11 cohorts patients that included follow-up...
Bacterial pneumonia is still a substantial cause of morbidity and mortality in HIV-infected patients the era combination Antiretroviral Therapy. The benefit tobacco withdrawal on risk bacterial has not been quantified such populations, exposed to other important factors as HIV-related immunodeficiency. Our objective was estimate effect smoking among individuals.
Nontuberculous mycobacteria (NTM) are environmental organisms associated with a range of infections. Reports NTM epidemiology mainly focused on pulmonary infections and isolations, extrapulmonary less frequently described.We conducted retrospective study at the Bordeaux University Hospital, France, between January 2002 December 2013. We used microbiologic component American Thoracic Society/Infectious Diseases Society America's disease criteria to define cases NTM, patients isolates from...
Abstract Background The objective of the study was to describe evolution chronic non-AIDS related diseases and their risk factors, in patients living with HIV (PLHIV) French ANRS CO3 Aquitaine prospective cohort, observed both 2004 2014 order improve long-term healthcare management. Methods cohort prospectively collects epidemiological, clinical, biological therapeutic data on PLHIV region. Two cross sectional analyses were performed 2014, investigate patient characteristics, RNA, CD4 counts...
Abstract Background Infliximab is currently recommended as a third-line treatment for refractory sarcoidosis. Data in function of clinical phenotype are lacking. We evaluated patients’ characteristics and responses to infliximab according their GenPhenReSa cluster. Methods biological patients diagnosed with sarcoidosis who received between September 2008 April 2019 at our centre. Results Fifty-five (median disease duration, 87 months) infliximab: 48 (87%) second- or treatment, 7 (13%)...